 Morphic Therapeutic NASDAQ: MORF has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease IBD. The data were shared at the Congress of European Crohns and Colitis Organization 2021 Virtual Congress. 